[go: up one dir, main page]

CN110114083A - 一种预防和治疗脂肪肝的方法 - Google Patents

一种预防和治疗脂肪肝的方法 Download PDF

Info

Publication number
CN110114083A
CN110114083A CN201780078127.7A CN201780078127A CN110114083A CN 110114083 A CN110114083 A CN 110114083A CN 201780078127 A CN201780078127 A CN 201780078127A CN 110114083 A CN110114083 A CN 110114083A
Authority
CN
China
Prior art keywords
fatty liver
prevent
subject
treat fatty
plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078127.7A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN110114083A publication Critical patent/CN110114083A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种预防和/或治疗受试者脂肪肝及其相关病症的方法,包括给药受试者有效量的纤溶酶原;另一方面,本发明还涉及用于预防和/或治疗受试者脂肪肝及其相关病症的包含纤溶酶原的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请,说明书已公开。

Claims (35)

  1. PCT国内申请,权利要求书已公开。
CN201780078127.7A 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法 Pending CN110114083A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110168 2016-12-15
CN2016110168 2016-12-15
CNPCT/CN2016/110172 2016-12-15
CN2016110172 2016-12-15
PCT/CN2017/089047 WO2018107688A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法

Publications (1)

Publication Number Publication Date
CN110114083A true CN110114083A (zh) 2019-08-09

Family

ID=62557882

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078105.0A Pending CN110366425A (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法
CN201780078118.8A Pending CN110167583A (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法
CN201780078127.7A Pending CN110114083A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201780078105.0A Pending CN110366425A (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法
CN201780078118.8A Pending CN110167583A (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法

Country Status (7)

Country Link
US (4) US11547746B2 (zh)
EP (4) EP3556391A4 (zh)
JP (4) JP7160351B2 (zh)
CN (4) CN110366425A (zh)
CA (4) CA3047167A1 (zh)
TW (9) TW201822812A (zh)
WO (8) WO2018107690A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101871A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
TW201822812A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療肥胖症的方法
CN110121357A (zh) 2016-12-15 2019-08-13 泰伦基国际有限公司 一种治疗糖尿病的新方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
JP7194440B2 (ja) 2016-12-15 2022-12-22 タレンゲン インターナショナル リミテッド 心臓病変を改善するための方法
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
WO2018233604A1 (zh) * 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
JP7616698B2 (ja) * 2020-02-26 2025-01-17 タレンゲン インターナショナル リミテッド 血圧異常症を予防及び治療する方法並びに薬剤
WO2021190563A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
CA3182911A1 (en) 2020-05-11 2021-11-18 Talengen International Limited Method and drug for treating spinal muscular atrophy
CN112056563A (zh) * 2020-09-15 2020-12-11 王胜林 用于修复脂质代谢障碍的营养素组合物及其应用
CN113041247A (zh) * 2021-04-21 2021-06-29 中山大学孙逸仙纪念医院 伊玛替尼在防治新型冠状病毒及并发症药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体
CN103384722A (zh) * 2011-01-05 2013-11-06 斯路姆基因公司 纤溶酶原和纤溶酶变体
US20130310305A1 (en) * 2011-02-10 2013-11-21 Trustees Of Dartmouth College Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (zh) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
WO2000049871A1 (en) * 1999-02-24 2000-08-31 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
US20070264194A1 (en) * 2001-08-10 2007-11-15 The Scripps Research Institute Peptides That Bind To Atherosclerotic Lesions
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
EP1472346A2 (de) 2002-02-06 2004-11-03 N-Zyme BioTec GmbH Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003301809A1 (en) 2002-05-13 2004-06-07 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
CN101396559A (zh) 2002-12-06 2009-04-01 法布罗根股份有限公司 糖尿病等的治疗
CN1726191A (zh) 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代的吲哚氧代-乙酰氨基乙酸衍生物
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
EP1666469A4 (en) 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF PLASMINOGENACTIVATORINHIBITOR-1
US20080017694A1 (en) 2003-09-24 2008-01-24 Alexander Schnell Braze Alloy And The Use Of Said Braze Alloy
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
DE602005022692D1 (de) 2004-04-22 2010-09-16 Talecris Biotherapeutics Inc Recombinant modifiziertes plasmin
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター-1阻害剤
WO2006102395A2 (en) * 2005-03-22 2006-09-28 Medstar Health Inc Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EP2000145A4 (en) 2006-03-24 2010-08-25 Rohto Pharma AGENT FOR ENHANCING METABOLIC SYNDROME
DK2056865T3 (en) 2006-08-28 2014-03-24 Omnio Healer Ab Hitherto unknown medicinal products for the prevention and treatment of gum disease, improvement of healing of gums in the gums and promotion of dental and oral health
JP5566105B2 (ja) 2006-08-28 2014-08-06 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
CA2666670A1 (en) 2006-10-20 2008-05-02 Dow Global Technologies Inc. Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
US20080200387A1 (en) 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
AT505574B1 (de) * 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
EP2201946A4 (en) 2007-10-23 2012-01-25 Inst Med Molecular Design Inc HAMMER OF PAI-1 PRODUCTION
CN101918548B (zh) * 2007-11-29 2013-10-16 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
KR101712208B1 (ko) 2008-01-09 2017-03-03 인트렉손 코포레이션 Pai―1 작용의 치료학적 억제제 및 이의 사용 방법
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
US20100209350A1 (en) * 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
US20120053222A1 (en) 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
CN102378753B (zh) 2009-03-31 2016-03-02 肾脏科学股份有限公司 纤溶酶原激活物抑制因子-1抑制剂
EP2424561A2 (en) 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
EP2464371B1 (en) 2009-08-12 2016-03-16 Cornell University Methods for preventing or treating metabolic syndrome
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) * 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
EP2566890A4 (en) 2010-05-03 2013-11-20 Abbvie Inc ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
US9044458B2 (en) * 2010-08-09 2015-06-02 The Johns Hopkins University Inhibition of tat activating regulatory DNA-binding protein 43
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
CA2829051C (en) 2011-03-03 2020-04-28 Tersus Pharmaceuticals, LLC Compositions and methods comprising c16:1n7-palmitoleate
CN102199587B (zh) * 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
SG193317A1 (en) * 2011-03-30 2013-10-30 Univ Texas Methods and compositions for targeting adipose cells in mammals
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
EP2914575B1 (en) 2012-10-31 2020-10-14 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
US9134326B2 (en) 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
CN105008320A (zh) * 2013-03-20 2015-10-28 埃莱万斯可再生能源科学股份有限公司 烷基酯和羧酸的酸催化低聚
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
MX2016001851A (es) 2013-08-13 2016-05-16 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
WO2015026494A2 (en) 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
TWI705822B (zh) 2014-12-19 2020-10-01 美商波麥堤克生物治療股份有限公司 包含纖維蛋白溶酶原之醫藥組合物及其用途
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
WO2017101869A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
DK3395359T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
JP7194440B2 (ja) 2016-12-15 2022-12-22 タレンゲン インターナショナル リミテッド 心臓病変を改善するための方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
TW201822812A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療肥胖症的方法
TWI868051B (zh) 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体
CN103384722A (zh) * 2011-01-05 2013-11-06 斯路姆基因公司 纤溶酶原和纤溶酶变体
US20130310305A1 (en) * 2011-02-10 2013-11-21 Trustees Of Dartmouth College Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 *
JI BEIER等: "Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism", 《EXPERIMENTAL BIOLOGY AND MEDICINE》 *
QING XIAO等: "Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis", 《PROC. NAT. ACAD. SCI. USA》 *

Also Published As

Publication number Publication date
WO2018107691A1 (zh) 2018-06-21
JP7161217B2 (ja) 2022-10-26
CN110114082A (zh) 2019-08-09
EP3556387A1 (en) 2019-10-23
CA3046664C (en) 2024-01-02
US20190328850A1 (en) 2019-10-31
WO2018107692A1 (zh) 2018-06-21
CA3046664A1 (en) 2018-06-21
WO2018107687A1 (zh) 2018-06-21
WO2018107690A1 (zh) 2018-06-21
CA3047168A1 (en) 2018-06-21
US20190351033A1 (en) 2019-11-21
EP3556387A4 (en) 2020-09-09
JP7158740B2 (ja) 2022-10-24
EP3556393A4 (en) 2020-11-25
TW202123963A (zh) 2021-07-01
US11478535B2 (en) 2022-10-25
WO2018107684A1 (zh) 2018-06-21
JP2020510627A (ja) 2020-04-09
TWI680764B (zh) 2020-01-01
EP3556394A1 (en) 2019-10-23
US11547746B2 (en) 2023-01-10
TW201822791A (zh) 2018-07-01
TW201822810A (zh) 2018-07-01
EP3556393A1 (en) 2019-10-23
JP2020502156A (ja) 2020-01-23
TW201822806A (zh) 2018-07-01
TW201822805A (zh) 2018-07-01
TWI684459B (zh) 2020-02-11
JP7160351B2 (ja) 2022-10-25
EP3556394A4 (en) 2020-11-25
TW201822809A (zh) 2018-07-01
WO2018107686A1 (zh) 2018-06-21
TWI746580B (zh) 2021-11-21
TW201822792A (zh) 2018-07-01
JP2020502154A (ja) 2020-01-23
WO2018107685A1 (zh) 2018-06-21
EP3556391A1 (en) 2019-10-23
TW201822812A (zh) 2018-07-01
CA3047167A1 (en) 2018-06-21
JP7214225B2 (ja) 2023-01-30
EP3556391A4 (en) 2020-09-09
JP2020511416A (ja) 2020-04-16
TW201822799A (zh) 2018-07-01
CN110167583A (zh) 2019-08-23
CA3047169A1 (en) 2018-06-21
CN110366425A (zh) 2019-10-22
WO2018107688A1 (zh) 2018-06-21
US20200078449A1 (en) 2020-03-12
US20200085920A1 (en) 2020-03-19
TWI750189B (zh) 2021-12-21

Similar Documents

Publication Publication Date Title
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2016065226A8 (en) Indole carboxamides compounds useful as kinase inhibitors
EP4349997A3 (en) Anti-garp antibody
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
HK1253734A1 (zh) 用作RORγ激動劑和用於治療疾病的芳基二氫-2H-苯並[B][1,4]噁嗪磺酰胺和相關化合物
CN110402150A (zh) 一种预防和治疗骨质疏松的药物及其用途
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
WO2016109217A3 (en) Btk inhibitors
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
WO2016142708A3 (en) Pharmaceutical composition
CN110114081A (zh) 一种改善心脏病变的方法
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
CN110167582A (zh) 一种预防和治疗药物性肾损伤的方法
CN110114080A (zh) 一种预防和治疗皮肤纤维化的方法
CN110520135A (zh) 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途
EP3586836A4 (en) PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT AND TREAT PANCREE CANCER, CONTAINING GOSSYPOL AND PHENFORMIN AS ACTIVE INGREDIENTS
JP2016069317A5 (ja) 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物
CN115666612A (zh) 一种治疗亨廷顿病的方法和药物
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
CN107148277A (zh) 一种抑制脂肪细胞分化和胰岛素耐受的药物
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination